海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300683 海特生物

交易中 12-08 13:01:33

{"stockData":{"symbol":"300683","market":"SZ","secType":"STK","nameCN":"海特生物","latestPrice":29.88,"timestamp":1765170093000,"preClose":29.51,"halted":0,"volume":1956599,"delay":0,"changeRate":0.0125,"floatShares":122000000,"shares":131000000,"eps":-1.434,"marketStatus":"交易中","change":0.37,"latestTime":"12-08 13:01:33","open":29.6,"high":30.35,"low":29.55,"amount":58687600,"amplitude":0.0271,"askPrice":29.87,"askSize":2,"bidPrice":29.84,"bidSize":24,"shortable":0,"etf":0,"ttmEps":-1.434,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765177200000},"marketStatusCode":2,"adr":0,"adjPreClose":29.51,"symbolType":"stock","openAndCloseTimeList":[[1765157400000,1765164600000],[1765170000000,1765177200000]],"highLimit":32.46,"lowLimit":26.56,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":130894391,"isCdr":false,"pbRate":1.73,"roa":"--","roe":"--","epsLYR":-0.53,"committee":0.771084,"marketValue":3911000000,"turnoverRate":0.016,"status":0,"floatMarketCap":3647000000},"requestUrl":"/m/hq/s/300683/wiki","defaultTab":"wiki","newsList":[{"id":"2589685060","title":"海特生物：截止2025年11月28日股东人数为19,014户","url":"https://stock-news.laohu8.com/highlight/detail?id=2589685060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589685060?lang=zh_cn&edition=full","pubTime":"2025-12-05 11:37","pubTimestamp":1764905855,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)12月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到2025年11月30日股东人数是多少？谢谢。海特生物回复：您好，感谢您的关注。截止2025年11月28日，公司股东人数为19,014户以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500013523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2586381647","title":"海特生物（300683）披露参股公司获得美国FDA新药临床试验批准通知，11月28日股价下跌2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586381647","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586381647?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:14","pubTimestamp":1764339267,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，海特生物报收于30.78元，较前一交易日下跌2.63%，最新总市值为40.29亿元。该股当日开盘32.01元，最高32.3元，最低30.66元，成交额达2.16亿元，换手率为5.68%。公司于近日发布公告称，其参股公司中眸医疗科技（武汉）有限公司申报的ZM-02眼用注射液治疗晚期视网膜色素变性的药物管线临床试验申请已获得美国FDA批准，同意开展临床研究。2024年10月，该药物获FDA孤儿药资格认定。目前该事项对公司近期经营业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2586200001","title":"海特生物最新公告：参股公司中眸医疗获美国FDA新药临床试验批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2586200001","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586200001?lang=zh_cn&edition=full","pubTime":"2025-11-28 17:24","pubTimestamp":1764321859,"startTime":"0","endTime":"0","summary":"海特生物(300683.SZ)公告称，公司参股公司中眸医疗的“ZM-02眼用注射液治疗晚期视网膜色素变性的药物管线”的临床试验申请获得美国FDA批准，同意其进行临床研究。ZM-02是中眸医疗自主研发的新一代光遗传学基因疗法，用于治疗晚期视网膜退行性疾病。此次获得临床试验批准对公司近期经营业绩不会产生重大影响。由于新药研发周期长、风险高，其临床试验进度及结果存在不确定性，公司将持续关注后续进展情况。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800025241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0239","300683"],"gpt_icon":0},{"id":"2584693559","title":"股市必读：海特生物(300683)股东户数1.99万户，较上期增加1.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584693559","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584693559?lang=zh_cn&edition=full","pubTime":"2025-11-17 02:49","pubTimestamp":1763318950,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，海特生物报收于34.5元，上涨0.7%，换手率7.05%，成交量8.61万手，成交额2.98亿元。来自股本股东变化：截至2025年11月10日，公司股东户数环比增加1.63%，户均持股数量下降至6591.0股。交易信息汇总资金流向11月14日主力资金净流入839.46万元；游资资金净流出802.1万元；散户资金净流出37.36万元。股本股东变化股东户数变动近日海特生物披露，截至2025年11月10日公司股东户数为1.99万户，较10月31日增加318.0户，增幅为1.63%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700001012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2583578067","title":"海特生物：截止2025年11月10日股东人数为19,861户","url":"https://stock-news.laohu8.com/highlight/detail?id=2583578067","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583578067?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:12","pubTimestamp":1763107934,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)11月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问11月10日的股东人数多少，谢谢海特生物回复：您好，感谢您的关注。截止2025年11月10日，公司股东人数为19,861户以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400024351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2582677723","title":"海特生物（300683）披露公司药品生产许可证变更公告，11月11日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582677723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582677723?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:43","pubTimestamp":1762872199,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，海特生物报收于34.3元，较前一交易日上涨0.41%，最新总市值为44.9亿元。该股当日开盘34.07元，最高34.72元，最低33.35元，成交额达3.24亿元，换手率为7.77%。公司近日发布公告称，武汉海特生物制药股份有限公司近日取得湖北省药品监督管理局换发的《药品生产许可证》，同意公司新增受托生产品种：注射用甲磺酸萘莫司他，委托方为福建大谱生物医药有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100041197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2581886079","title":"海特生物（300683）披露2025年第一次临时股东大会法律意见书，11月07日股价下跌0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581886079?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:18","pubTimestamp":1762525127,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，海特生物报收于32.58元，较前一交易日下跌0.52%，最新总市值为42.65亿元。该股当日开盘32.6元，最高34.3元，最低32.58元，成交额达3.18亿元，换手率为7.81%。公司近日发布公告，北京中伦（武汉）律师事务所就武汉海特生物制药股份有限公司2025年第一次临时股东大会的召集程序、召开程序、出席人员资格、表决程序及表决结果出具法律意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700039138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"gpt_icon":0},{"id":"2580201703","title":"海特生物：截止2025年10月31日股东人数为19,543户","url":"https://stock-news.laohu8.com/highlight/detail?id=2580201703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580201703?lang=zh_cn&edition=full","pubTime":"2025-11-04 15:03","pubTimestamp":1762239797,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问10月31日股东人数是多少？海特生物回复：您好，感谢您的关注。截止2025年10月31日，公司股东人数为19,543户以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400018493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"gpt_icon":0},{"id":"2580526152","title":"海特生物：埃普奈明用于治疗多发性骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2580526152","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580526152?lang=zh_cn&edition=full","pubTime":"2025-11-03 15:42","pubTimestamp":1762155726,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)11月03日在投资者关系平台上答复投资者关心的问题。投资者提问：四川华西引进新药埃普奈明是哪个厂家的？这药治什么病？毛利率多少？海特生物回复：您好，感谢您的关注。埃普奈明是公司于2023年11月获批的一款重组蛋白类抗肿瘤新药，通过联合沙利度胺和地塞米松用于既往接受过至少2种系统性治疗方案的复发或难治性多发性骨髓瘤成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300015969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"gpt_icon":0},{"id":"2579977301","title":"业绩连亏、现金流告急、股价破发，海特生物赴港“输血”悬念重重","url":"https://stock-news.laohu8.com/highlight/detail?id=2579977301","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579977301?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:01","pubTimestamp":1761814860,"startTime":"0","endTime":"0","summary":"海特生物正在经历上市以来最严峻的考验。2025年三季报显示，公司前三季度净亏损同比扩大近三倍至1.58亿元，单季度亏损更创下历史新高。而在这份“成绩单”背后，是公司连续三年的亏损累积、核心产品失速、并购拖累加重、现金流持续恶化的多重困境。　　面对A股市场的融资收紧与自身经营的持续失血，海特生物近期宣布启动H股发行筹备工作，拟赴港上市“补血”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-10-30/doc-infvskcs4168442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159399","BK0239","300683"],"gpt_icon":0},{"id":"2577253799","title":"海特生物（300683）2025年三季报简析：净利润同比下降297.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577253799","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577253799?lang=zh_cn&edition=full","pubTime":"2025-10-24 06:05","pubTimestamp":1761257128,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期海特生物发布2025年三季报。根据财报显示，海特生物净利润同比下降297.78%。截至本报告期末，公司营业总收入4.22亿元，同比下降6.45%，归母净利润-1.58亿元，同比下降297.78%。按单季度数据看，第三季度营业总收入1.47亿元，同比下降11.74%，第三季度归母净利润-1.19亿元，同比下降600.39%。本次财报公布的各项数据指标表现不尽如人意。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400004889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683"],"gpt_icon":0},{"id":"2577629993","title":"海特生物(300683.SZ)发布前三季度业绩，归母净亏损1.58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577629993","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577629993?lang=zh_cn&edition=full","pubTime":"2025-10-22 20:53","pubTimestamp":1761137588,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海特生物(300683.SZ)发布2025年三季度报告，该公司前三季度营业收入为4.22亿元，同比减少6.45%。归属于上市公司股东的净亏损为1.58亿元。归属于上市公司股东的扣除非经常性损益的净亏损为1.8亿元。基本每股亏损为1.21元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"海特生物(300683.SZ)发布前三季度业绩，归母净亏损1.58亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2574437139","title":"海特生物：截止9月30日公司股东人数为16,437户","url":"https://stock-news.laohu8.com/highlight/detail?id=2574437139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574437139?lang=zh_cn&edition=full","pubTime":"2025-10-09 16:06","pubTimestamp":1759997186,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)10月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止至2025年9月30日收盘公司股东人数为多少，谢谢！海特生物回复：您好，感谢您对公司的关注。截止9月30日公司股东人数为16,437户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900017873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2571825828","title":"股市必读：海特生物（300683）9月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2571825828","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571825828?lang=zh_cn&edition=full","pubTime":"2025-09-29 01:12","pubTimestamp":1759079534,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，海特生物报收于34.1元，下跌2.26%，换手率4.62%，成交量5.64万手，成交额1.93亿元。董秘最新回复投资者： 请问贵司的埃普奈明有研究其他适应症吗？埃普奈明有进行其他临床适应症的研究，由研究者发起的临床研究已经在骨肉瘤、淋巴瘤方面开展，后期待样本量及数据足够后公司也会适时开展注册临床工作。当日关注点来自交易信息汇总：9月26日主力资金净流出2528.12万元，散户资金净流入2629.41万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900000553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"gpt_icon":0},{"id":"2570776008","title":"海特生物：埃普奈明有进行其他临床适应症的研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2570776008","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570776008?lang=zh_cn&edition=full","pubTime":"2025-09-26 16:24","pubTimestamp":1758875049,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)09月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司的埃普奈明有研究其他适应症吗？进展如何？海特生物回复：尊敬的投资者，您好！埃普奈明有进行其他临床适应症的研究，由研究者发起的临床研究已经在骨肉瘤、淋巴瘤方面开展，后期待样本量及数据足够后公司也会适时开展注册临床工作。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600025569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2569774735","title":"海特生物(300683)9月19日股东户数1.59万户，较上期增加2.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569774735","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569774735?lang=zh_cn&edition=full","pubTime":"2025-09-24 17:23","pubTimestamp":1758705822,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海特生物披露，截至2025年9月19日公司股东户数为1.59万户，较9月10日增加356.0户，增幅为2.29%。在医疗服务行业个股中，海特生物股东户数低于行业平均水平，截至9月19日，医疗服务行业平均股东户数为4.48万户。从股价来看，2025年9月10日至2025年9月19日，海特生物区间跌幅为7.48%，在此期间股东户数增加356.0户，增幅为2.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092400030156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"gpt_icon":0},{"id":"2566930297","title":"海特生物：截止9月10日公司股东人数为15,530户","url":"https://stock-news.laohu8.com/highlight/detail?id=2566930297","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566930297?lang=zh_cn&edition=full","pubTime":"2025-09-11 11:37","pubTimestamp":1757561823,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请告知9月10日收盘后公司的股东人数是多少？谢谢！海特生物回复：您好，感谢您对公司的关注。截止9月10日公司股东人数为15,530户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100014578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"gpt_icon":0},{"id":"2564874119","title":"海特生物：截止8月29日公司股东人数为14,620户","url":"https://stock-news.laohu8.com/highlight/detail?id=2564874119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564874119?lang=zh_cn&edition=full","pubTime":"2025-09-02 15:57","pubTimestamp":1756799829,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)09月02日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，截至8月底公司的股东人数是多少？请告知，谢谢！海特生物回复：您好，感谢您对公司的关注。截止8月29日公司股东人数为14,620户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200023685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2562006822","title":"生物制品板块异动下跌，海特生物领跌6.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562006822","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562006822?lang=zh_cn&edition=full","pubTime":"2025-08-26 14:48","pubTimestamp":1756190883,"startTime":"0","endTime":"0","summary":"8月26日，生物制品板块盘中下跌1.51%，海特生物领跌6.99%，欧林生物、舒泰神跌超6%，益方生物-U跌超5%，三生国健跌超4%。板块实时资金流向显示，今日超大单净流出7.83亿元，今日小单净流入3.64亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26144852694833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","300683"],"gpt_icon":0},{"id":"2562728422","title":"海特生物：截止8月20日公司股东人数为13,430户","url":"https://stock-news.laohu8.com/highlight/detail?id=2562728422","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562728422?lang=zh_cn&edition=full","pubTime":"2025-08-26 08:46","pubTimestamp":1756169172,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)08月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司8.20日股东人数海特生物回复：您好，感谢您对公司的关注。截止8月20日公司股东人数为13,430户。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082600010806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765170100606,"stockEarnings":[{"period":"1week","weight":-0.0413},{"period":"1month","weight":-0.1135},{"period":"3month","weight":-0.3097},{"period":"6month","weight":0.1203},{"period":"1year","weight":0.081},{"period":"ytd","weight":0.2451}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉海特生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19014人(较上一季度减少4.26%)","perCapita":"6419股","listingDate":"2017-08-08","address":"湖北省武汉市蔡甸区经济技术开发区海特科技园","registeredCapital":"13089万元","survey":"　　武汉海特生物制药股份有限公司的主营业务是大分子生物药、小分子化学药、原料药与医药中间体的生产销售，同时也为国内外的制药企业提供制剂和原料药的CRO、CMO和CDMO技术服务。公司的主要产品是神经损伤修复类药物、治疗用生物制品、化学药物、药学研究、CRO临床业务。报告期内，公司荣获“2024年度中国车谷经济高质量发展企业”称号、公司的“注射用鼠神经生长因子”、“注射用埃普奈明”两个产品被列入《湖北省创新产品应用示范推荐目录》（2024年版）。","listedPrice":32.94},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海特生物(300683)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海特生物,300683,海特生物股票,海特生物股票老虎,海特生物股票老虎国际,海特生物行情,海特生物股票行情,海特生物股价,海特生物股市,海特生物股票价格,海特生物股票交易,海特生物股票购买,海特生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海特生物(300683)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}